Armando Orlandi, Medical Oncologist at Agostino Gemelli University Policlinic, shared an article by Maurizio Callari, et al. on X:
“Cowabunga!
Riding Breast Cancer‘s Biggest Data’s Wave from Literature.
NA-PHER2 study shows HER2+/ER+ breast cancers can be treated without chemo!
High TIL + low ER signaling = 72.7% pCR. TP53 mutations spell trouble though!
Targeting PAK4 for RD?”
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.
Authors: Maurizio Callari, et al.
